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Abstract
Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) is a hybrid of two technologies each
with its own evidence for clinical effectiveness. This article amalgamates evidence for clinical effectiveness of
fluorodeoxyglucose (FDG) PET/CT and MRI as separate modalities with current evidence for hybrid PET/MRI and
considers whether such an approach might provide a stronger case for the clinical use of PET/MRI at an earlier stage.
Because links between diagnostic accuracy and health outcomes have already been established for FDG-PET/CT in the
investigation of suspected residual or recurrent malignancies, evidence showing improved diagnostic performance and
therapeutic impact from the use of PET/MRI as an alternative would imply clinical effectiveness of this modality for this
application. A meta-analysis of studies comparing FDG-PET/CT to MRI in patients with suspected residual disease or
recurrence of tumours indicates complementary roles for these modalities. PET demonstrates greater sensitivity for
recurrence within lymph nodes whereas MRI is more effective that PET/CT in the detection of skeletal and hepatic
recurrence. A review of studies assessing therapeutic impact of PET/MRI suggests a greater likelihood for change in
clinical management when PET/MRI is used for assessment of suspected residual or recurrent disease rather than
tumour staging.
Supplementing the evidence-base for FDG-PET/MRI with studies that compare the components of this hybrid
technology deployed separately indicates that FDG-PET/MRI is likely to be clinical effective for the investigation of
patients with a range of suspected residual or recurrent cancers. This indication should therefore be prioritised for
further health technology assessment.
Background
William Osler’s description of medicine as “a science of
uncertainty and an art of probability” is as pertinent now
as it was in his time [1]. A frequent area of uncertainty
in medicine today relates to the introduction of emer-
ging health technologies, where early adoption is often
associated with lack of clarity regarding the clinical ap-
plications that add value for patients and society. This
situation reflects the current status of Positron Emission
Tomography/Magnetic Resonance Imaging (PET/MRI)
in oncology. The ability to simultaneously acquire PET
images of tissue function and MRI images of soft tissue
morphology represents a technological advance on
PET/Computed Tomography (CT) which is currently
used widely for staging and assessment of suspected
residual or recurrent disease in patients with a range
of tumour types.
Whilst recognising the potential for PET/MRI to im-
pact on priority health areas, recent technology briefs in
Australia and the UK have both highlighted the need for
better evidence of clinical effectiveness for this technol-
ogy [2, 3]. Emerging technologies typically have a limited
evidence-base from which to identify clinical applica-
tions and accumulation of sufficient evidence to justify
clinical use may take a significant amount of time.
However, hybrid devices such as PET/MRI do not repre-
sent a completely new technology, but integrate two
pre-existing technologies each with its own evidence for
clinical effectiveness. A different approach to evidence
synthesis that assimilates data for PET/CT and MRI as
separate modalities could therefore potentially supple-
ment the currently limited evidence derived using hybrid
PET/MRI systems. This article considers whether such
an approach might provide a stronger case for the clin-
ical use of PET/MRI at an earlier stage.
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Technical advantages of PET/MRI
An important technical advantage for PET/MRI is a re-
duction radiation exposure for patients. With PET/CT,
the CT component is used for attenuation correction,
and for the localisation and characterisation of lesions
identified by PET. Although attenuation correction is
achieved using a low-dose protocol, additional diagnostic
quality CT acquisitions may be required for accurate le-
sion localisation and characterisation. If these CT acqui-
sitions are replaced by MRI, it can be estimated that
dose reductions of 1.5 to 19.4 mSv per examination
could be achieved [4]. There are also opportunities to re-
duce the amount of radiotracer administered.
Secondly, the high tissue contrast afforded by MRI of-
fers the potential to compensate for some diagnostic
limitations of PET/CT, such as the constraints created
by background physiological tracer uptake in certain or-
gans. For the most commonly used clinical PET tracer,
Fluorodeoxyglucose (FDG), the reduced sensitivity of
PET for cerebral metastases due to high physiological ra-
diotracer uptake is sufficiently well recognised for brain
MRI to be frequently included in current care pathways.
However, there is also significant physiological FDG up-
take in liver and bone marrow and addition of appropri-
ate MRI sequences to FDG-PET could similarly improve
detection of metastatic disease in these organs. Appro-
priate whole-body MRI acquisitions for detection of
skeletal metastases can be acquired concurrently with
the whole-body PET images. For maximal detection of
liver lesions, an additional dedicated series of acquisi-
tions in a single bed-position can be readily appended to
the whole-body acquisitions, including images with
liver-specific contrast material [5]. The multiple MR
sequences acquired in this way can also potentially
improve tissue characterisation in comparison to CT, for
example aiding the distinction between malignant and
inflammatory causes of FDG uptake.
Advantages of PET/MRI over separately acquired PET/CT
and MRI
An important consideration for clinical PET/MR is the
extent to which simultaneous PET/MR benefits over se-
quential PET/CT and MRI acquisitions with either side-
by-side interpretation or software fusion. Acquiring PET
and MRI data sets on a single device avoids duplication
of booking procedures, saves time and number of de-
partmental visits for the patient, and avoids the radiation
dose associated with the low-dose CT component of
PET-CT. Simultaneous acquisition of PET and MR im-
ages results in highly accurate anatomical registration
that is more readily integration into clinical workflow
than software co-registration of separately acquired
PET/MRI data sets. Furthermore, software fusion ap-
proaches cannot reliably compensate for the differences
in respiration, peristalsis, and filling of bowel and blad-
der that frequently occur between images of thorax, ab-
domen and pelvis acquired at different times [6]. Image
co-registration afforded by PET/MRI is also superior to
that achievable with PET/CT devices which acquire the
image datasets sequentially, albeit in close temporal
proximity on the same imaging table, resulting in greater
confidence in assignment of areas of radiotracer uptake
to anatomical findings [7]. Studies comparing side-by-
side interpretation with integrated image acquisition for
other hybrid imaging modalities such as SPECT/CT
and PET/CT have confirmed that more accurate co-
registration of functional and anatomical datasets is
associated with greater diagnostic specificity and fewer
indeterminate reports and such benefits can be also be
anticipated for PET/MRI [8, 9]. There are also oppor-
tunities for PET/MR to improve quantification of radio-
tracer uptake by more accurate compensation for body
composition and/or intra-lesional fat, analogous to
methods proposed for brain PET/MRI [10].
Patient groups who may benefit from PET/MRI
Reductions in radiation exposure due diagnostic imaging
would be a particular advantage for paediatric patients.
However, as the incidence of cancer in this population is
relatively low, the burden of disease is unlikely to justify
installation of PET/MR outside highly specialised cen-
tres. A second group of patients for whom radiation ex-
posure from diagnostic tests is emerging is a significant
issue comprises cancer survivors. A recent study has es-
timated the risk of second cancer induction by the use
of CT in this group of patients to be between 0.1 and
10 % [11]. With the growing success of first-line cancer
therapy leading to an increasing population of cancer
survivors, survivorship is emerging as a significant chal-
lenge for health care. For example, it has been estimated
that 13.7 million cancer survivors were living in the US
as of January 2012 as compared to 1.6 million new can-
cer cases diagnosed in the US that year, a ratio greater
than 8:1 [12]. Diagnostic imaging, including PET/CT, is
frequently used in cancer survivors when residual or re-
current disease is suspected on the basis of symptoms or
rising tumour markers. If tumour is excluded, patients
can continue routine surveillance. If residual or recur-
rent tumour is confirmed, patients with localised disease
may benefit from surgery or other local therapy such as
stereotactic ablative radiotherapy, whereas second-line
chemotherapy or best-supportive care would be appro-
priate for patients with extensive disease. Alternatively,
imaging instigated for suspected recurrence may also
reveal a second malignancy. In this clinical context, re-
sidual disease needs to be distinguished from post-
treatment inflammatory change whilst the brain, liver and
bone marrow are common sites for disease recurrence.
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Thus, this group of patients could also benefit from the
potential for PET/MRI to overcome current limitations of
PET/CT in this clinical context.
Evaluating evidence for clinical effectiveness of hybrid
imaging technologies
Clinical effectiveness of a diagnostic test is defined by
the extent to which incorporating the test into clinical
practice improves health outcomes [13]. Direct evidence
of the impact of a diagnostic test on health outcomes is
rarely available due to a range of methodological difficul-
ties. Clinical effectiveness can therefore also be demon-
strated by using evidence that links test accuracy with
evidence that the test result changes treatment practice,
and with evidence that the alternative treatments have
different effectiveness and safety profiles [13]. Links be-
tween diagnostic accuracy and health outcomes have
already been established for a range of clinical applica-
tions for PET and MRI as separate modalities. For inves-
tigation of suspected residual or recurrent malignancies,
strong links have been established between FDG-PET
and clinical outcome for patients with lymphoma, sar-
coma, malignant melanoma and cancers of the colon or
rectum, ovary, uterine cervix, and head & neck. The key
issues for the clinical effectiveness of hybrid PET/MRI
devices in the assessment of suspected residual or recur-
rent malignancy are therefore a) the extent to which
combining these modalities can improve diagnostic per-
formance compared to either modality alone, and b)
whether any improvements diagnostic performance lead
to changes in treatment practice.
Comparative studies of diagnostic accuracy of FDG-PET
and MRI for residual/recurrent malignancy
The Cochrane Collaboration has stipulated standards for
the analysis of comparative studies of diagnostic accur-
acy [14]. To minimise bias, such studies employ a direct
comparison of the tests in question by either applying
both tests to each individual, or randomising each indi-
vidual to receive one of the tests. A common reference
standard should be consistently applied to both tests.
Nine studies that meet these standards whilst reporting
the accuracy of MRI and FDG-PET in patients with sus-
pected residual or recurrent disease for the tumour types
listed above are available [15–23].
Detection of tumour recurrence within lymph nodes, bone
and liver
Seven publications have reported the diagnostic perfor-
mances of PET/CT and MRI in the detection of nodal,
skeletal or hepatic metastases in patients clinically sus-
pected to have recurrent tumours [15–21]. Three of these
reports considered patients with recurrent melanoma
(total number of patients = 136), one study comprised
patients with recurrent colorectal (24 patients), one study
considered patients with head and cancer (179 patients)
and 2 studies included patients with various non-central
nervous system tumours (total number of patients = 72).
For each study the reference standard consisted of hist-
ology or clinical follow-up for at least 6 months.
These studies indicate complementary roles for PET
and MRI in identification of tumour recurrence. FDG-
PET/CT demonstrates superior diagnostic performance
for recurrence in lymph nodes whilst recurrences in the
skeleton and liver are more reliably depicted by MRI
(Fig. 1). The weighted averages from the 5 studies
reporting diagnostic performance for detection of nodal
recurrence (Table 1) show superior sensitivity for PET/
CT with no significant change in positive predictive
value (PPV) whereas the weighted averages of the 5
studies reporting diagnostic performance for detection
of skeletal recurrence (Table 2) and the 5 studies com-
paring PET/CT and MRI in the detection of tumour re-
currence within the liver (Table 3) both confirm superior
sensitivity for MRI with no significant difference in PPV.
Identification of patients with tumour recurrence
Three studies compared the performance of FDG-PET/
CT to combined reading of PET/CT and MRI in patients
with suspected tumour recurrence (Table 4). The first
comprised a meta-analysis which identified 4 studies that
comparing the diagnostic performance on a per-patient
Fig. 1 PET/MRI study comprising whole-body FDG-PET (a) and Short
Tau Inversion Recovery (STIR) MRI (b) from a patient with recurrent
myxoid liposarcoma. The skeletal metastases are more readily
appreciated on the MRI than on FDG-PET
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basis of PET/CT alone to PET combined with WB-MRI
in the detection of residual or recurrent tumour of the
head and neck [22]. Combined reading improved the
sensitivity for the identification of patients with residual
or recurrent disease from 82 % (95 % CI: 69–90 %) to
89 % (95 % CI: 86–96 %) with no loss of specificity
(PET-CT: 97 [94–98]%; combined reading: 98 [97–99]%).
Additional to the above meta-analysis, in a study of 67 pa-
tients undergoing both dedicated PET/MRI and PET/CT,
Biederwellen et al. [23] reported a trend for improved sen-
sitivity when using PET/MRI (100 %, [95 % CI: 72–100 %]
versus 90 % [68–98 %] for PET/CT) with no change in
specificity (each 100 %; [94–100]%). On the other hand, a
study of 37 patients by Donati et al. found no significance
difference in the ability of retrospectively fused PET and
MRI data sets compared to PET-CT to identify patients
with liver metastases [21].
Changes in treatment practice from FDG-PET/MRI for
patients suspected residual or recurrent malignancy
Three studies have reported therapeutic impact from the
use of PET/MRI in place of PET/CT [7, 24, 25] (Table 5).
Two of these studies [24, 25] included patients with sus-
pected residual disease or recurrence whereas the study by
Al-Nabhani et al. [7] comprised only patients for staging.
The likelihood of PET/MRI detecting additional findings
Table 1 Summary of the results of test accuracy in studies comparing whole-body MRI with FDG-PET/CT in the detection of sites of
tumour recurrence within lymph nodes
Study Population & setting Reference standard Outcome [95 % CI]
PET-CT WB-MRI
Sensitivity PPV Sensitivity PPV
Pfannenberg et al. (2007) [15] Recurrent melanoma Histology or 8 months
follow-up
85 [77–91] % 94 % [87–97] % 66 [56–74] % 84 % [74–90] %
Self-controlled study (n = 64)
Schmidt et al. (2009) [16] Recurrent Colorectal Cancer Follow-up (mean 11
months)
93 [78–98] % 100 [86–100] % 62 [44–77] % 82 [61–93] %
Self-controlled study (n = 24)
Ng et al. (2010) [18] Recurrent Head & Neck Cancer Histology or 12 months
follow-up
80 [61–91] % 77 [58–89] % 88 [70–96] % 81 [63–92] %
Self-controlled study (n = 179)
Laurent et al. (2010) [19] Recurrent melanoma Histology or 6 months
follow-up
83 [65–92] % 100 [86–100] % 90 [74–96] % 96 [82–99] %
Self-controlled study (n = 35)
Jouvet et al. (2014) [20] Recurrent melanoma Histology or ≥6 months
follow-up
96 [79–99] % 96 [79–99] % 87 [68–95] % 100 [84–100] %
Self-controlled study (n = 37)
Weighted averages (n = 339) 87 [81–91] % 93 [89–96] % 74 [67–79] % 87 [81–91] %
Table 2 Summary of the results of test accuracy in studies comparing whole-body MRI with FDG-PET/CT in the detection of sites of
skeletal metastases
Study Population & setting Reference standard Outcome [95 % CI]
PET-CT WB-MRI
Sensitivity PPV Sensitivity PPV
Pfannenberg et al. (2007) [15] Recurrent melanoma Histology or 8 months
follow-up
91 [78–97] % 91 % [78–97] % 100 [90–100] % 90 % [76–96] %
Self-controlled study (n= 64)
Schmidt et al. (2007) [16] Non-CNS tumours and
suspicion of bone
metastases
≥6 months imaging
follow-up
77 [68–84] % 94 [67–97] % 94 [88–97] % 94 [88–97] %
Self-controlled study (n= 35)
Schmidt et al. (2009) [17] Recurrent Colorectal Cancer Follow-up (mean 11
months)
50 [15–85] % 100 [51–100] % 100 [51–100] % 100 [51–100] %
Self-controlled study (n= 24)
Laurent et al. (2010) [19] Recurrent melanoma Histology or 6 months
follow-up
71 [45–88] % 100 [72–100] % 93 [69–99] % 100 [77–100] %
Self-controlled study (n= 35)
Jouvet et al. (2014) [20] Recurrent melanoma Histology or ≥6 months
follow-up
88 [64–97] % 93 [70–99] % 100 [81–100] % 76 [55–89] %
Self-controlled study (n = 37)
Weighted averages (n = 195) 80 [74–85] % 94 [89–97] % 96 [92–98] % 92 [87–95] %
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not identified on PET/CT with impact on clinical manage-
ment is much greater in the studies including patients with
suspected recurrence (Odds ratio 14.4 or infinity versus
2.1). The largest of these studies (Catalano et al.) also
reported the incidence of change in management for
different categories of additional finding. Change in
clinical management was significantly more likely when
additional findings related to recurrent or residual dis-
ease (Odds ratio calculated from reported data = 10.4,
95 % CI 2.9 – 37, p <0.0001).
The need for further clinical evaluation of PET/MRI in
residual/recurrent malignancy
There are areas in which the evidence-based for PET/MRI
in the assessment of suspected residual or recurrent
malignancy is deficient. Current management of residual/
recurrent tumour requires stratification of patients beyond
the presence or absence of tumour. Local treatments
such as surgery or radiotherapy may be appropriate for
patients with localised recurrence whereas systemic
treatment such as chemotherapy or palliative treatment
would be most appropriate for disseminated disease.
Using the available literature, it has not been possible
to assess the potential impact of PET/MRI over PET/
CT in stratifying patients as described above and we
highlight the need for such studies in future. Further-
more, even after the evidence-synthesis described in
our study, current literature is not sufficiently mature
to enable an assessment of whether the implied effect-
iveness of PET/MRI in recurrent/residual malignancy is
Table 3 Summary of the results of test accuracy in studies comparing whole-body MRI with FDG-PET/CT in the detection of sites of
tumour recurrence within the liver
Study Population & setting Reference standard Outcome [95 % CI]
PET-CT WB-MRI
Sensitivity PPV Sensitivity PPV
Donati et al. (2010) [21] Various (n= 37, Colorectal
Cancer: n= 20)
Histology or follow-up 76 [64–86] % 93 [82–98] % 91 [80–96] % 100 [93–100] %
Schmidt et al. (2009) [16] Recurrent Colorectal
Cancer
Follow-up (mean
11 months)
86 [65–95] % 100 [82–100] % 100 [85–100] % 100 [85–100] %
Self-controlled study
(n = 24)
Pfannenberg et al. (2007) [15] Recurrent melanoma Histology or 8 months
follow-up
94 [81–98] % 100 [90–100] % 100 [90–100] % 100 [90–100] %
Self-controlled study
(n = 64)
Laurent et al. (2010) [19] Recurrent melanoma Histology or 6 months
follow-up
50 [15–85] % 100 [51–100] % 100 [51–100] % 100 [51–100] %
Self-controlled study
(n = 35)
Jouvet et al. (2014) [20] Recurrent melanoma Histology or ≥6 months
follow-up
100 [76–100] % 100 k[76–100] % 100 [76–100] % 92 [67–99] %
Self-controlled study
(n = 37)
Weighted averages (n = 90) 84 [77–90] % 97 [92–99] % 96 [91–98] % 99 [96–100] %
Table 4 Summary of the results of test accuracy in studies comparing combined MRI and FDG-PET/CT to PET/CT alone for the
classification of patients with or without tumour recurrence
Study Population & setting Reference standard
and comparator
Outcome [95 % CI]
PET/CT PET/MR
Sensitivity Specificity Sensitivity Specificity
Xu et al. (2013) [22] Meta-analysis of 4 studies
comparing PET/CT and
WB-MRI in the detection
metastatic head & neck
cancer (n = 511)
Reference standard variable. 82 [69–90] % 97 [94–98] % 89 [86–96] % 98 [97–99] %
Combined reading of
PET and WB-MRI
Donati et al. (2010) [21] Hepatic metastases
(n = 37, CRC: n = 20)
Histology or follow-up
Fused PET/MR
100 [77–100] % 92 [67–99] % 100 [77–100] % 100 [77–100] %
Beiderwellen et al.
(2014) [23]
Skeletal metastases
(n = 67)
Histology or follow-up 90 [68–98] % 100 [72–100] % 100 [94–100] % 100 [94–100] %
Dedicated PET/MR
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likely to be cost-effective. The capital cost of PET/MRI
devices are comparable to PET/CT and MRI systems
purchased separately and therefore, to ensure cost-
effectiveness, PET/MRI workflows need to minimise
the amount of time when either component is idle.
Where PET/MRI replaces PET/CT and MRI performed
separately, streamlining of clerical, radiographer and
nursing work related to imaging investigation of pa-
tients with residual or recurrent cancer into a single
imaging episode may defray some of these costs. On the
other hand, potential improvements in cost-effectiveness
can be anticipated. The therapeutic impact study of
Catalano et al. found the commonest change in man-
agement when PET/MRI was used for patient with re-
sidual or recurrent disease was avoidance of biopsy
[24]. Further management changes of potential health
economic importance include avoiding the cost and
morbidity of futile local treatments that would have
been inappropriately selected due to under-estimation of
disease extent by current technology, earlier identification
of limited or disseminated disease allowing timely instiga-
tion of local therapy or salvage therapy respectively, and
avoidance of futile chemotherapy in the presence of ad-
vanced disease of an extent under-estimated by current
technology. Future studies are also needed to address
these aspects of PET/MRI deployment.
Other potential benefits of PET/MRI are less tangible
than those that can be inferred from improved diagnos-
tic performance and therapeutic impact over PET/CT.
Combining into a single procedure, examinations that in
some instances may have been performed on separate
devices and/or separate occasions using current technol-
ogy, will result in increased convenience for patients
such as reduced travel costs and fewer attendance days,
with more rapid availability of the results of imaging
assessment allowing earlier clinical decision making.
Deployment of PET/MRI could also usefully increase
capacity for MRI at a time when utilisation of MRI for
oncological applications is increasing [26]. The impact of
the reduced radiation exposure for patients from the use
of MRI in place of CT can also be anticipated to improve
health outcomes by reducing the risks of second cancer
induction which have been shown to be significant for
cancer survivors [11]. However, such benefits are harder
to quantify in health economic terms and are not typic-
ally included in economic analyses of diagnostic imaging
technologies. The impact of reduced risk of adverse re-
action to contrast material for those situations where
PET/MRI has replaced PET/CT with contrast enhance-
ment is similarly hard to quantify.
The approach to evidence-based synthesis outlined
above for FDG-PET is currently not applicable for other
PET tracers with emerging roles in oncology such as
68Ga-dotatate and 68Ga-Prostate Specific Membrane
Antigen because the evidence-based for these tracers is
underdeveloped in comparison to FDG. In particular,
there is a paucity of data linking the use of these tracers
with improvements in health outcomes and few studies
comparing their use with PET/CT against whole-body
MRI. Therefore, the clinical effectiveness of these emer-
ging tracers will need to be evaluated using conventional
approaches to health technology assessment approaches.
Considerations for PET/MRI service delivery
There are a range of further issues that would need to
be addressed before implementing clinical PET/MRI for
evaluation of suspected residual or recurrent disease.
Firstly, there would need to be sufficient patients with
relevant clinical need. Secondly, PET/MRI would need
to co-located with PET/CT to ensure available of PET
for patients with contraindications to MRI (e.g., MR in-
compatible implantable medical devices, previous ocular
metallic foreign body) and to meet the circumstances
when PET/CT may be superior to PET/MRI, for ex-
ample the visualisation of small pulmonary nodules.
Overall imaging demand would therefore need to justify
Table 5 Summary table for studies reporting therapeutic impact
Study Population Outcome New Technology n
with event/N (%)
Comparator n
with event/N (%)
Effect size
(95 % CI/p value)
Catalano et al.
(2013) [24]
Cohort observational study.
Staging or follow-up of
non-CNS tumours (n = 134)
Patients additional findings not
identified on alternate modality
6/134 (4.5 %) 55/134 (41 %) OR: 14.9 (6.1–36.1
p <0.0001)
Patients with additional findings
not identified on alternate modality
affecting clinical management
24/134 (17.9 %) 2/134 (1.5 %) OR: 14.4 (3.3–62.3
p <0.0001)
Reiner et al.
(2014) [25]
Cohort observational study.
Hepatic metastases (n = 55,
CRC: n = 41)
Patients additional findings not
identified on alternate modality
8/55 (9.1 %) 0/55 (0 %) OR: Infinity OR: Infinity
Patients with additional findings
not identified on alternate modality
affecting clinical management
5/55 (9.1 %) 0/55 (0 %)
Al-Nabhani et al.
(2014) [7]
Cohort observational study.
Staging of non-CNS tumours
(n = 50)
Patients with additional findings
not identified on alternate modality
affecting clinical management
4/50 (8 %) 1/50 (2 %) OR: 2.1 (0.36–11.9 NS)
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2 PET systems (one PET/MRI and one PET/CT) and
thus a regional oncology centre would likely be the most
appropriate location for such a service. Even under these
circumstances, PET/MRI research and/or additional
standalone MR examinations would likely be needed to
completely fill the capacity of the PET/MRI installation.
Although the clinical component of such a combined
program may be based on a remote supply of FDG,
colocation with a cyclotron would facilitate a parallel
PET/MR research program by making other PET tracers
available for oncological research. Furthermore, the clin-
ical and research components of such a programme
would each require availability and co-ordination of
technical and radiological expertise in both nuclear
medicine and oncologic MRI. Funding of a clinical FDG-
PET/MRI service may also be problematic as, depending
on the relevant health-care system, if accessible at all,
re-imbursement may only be available at the same level
as PET/CT. Studies demonstrating the cost-effectiveness
of PET/MR in comparison to PET/CT may be required
before a level of reimbursement reflecting the additional
cost associated with PET/MRI becomes available.
Conclusion
This review has illustrated two issues related to evidence-
based assessments of hybrid imaging technologies such as
PET/MRI. Firstly, the requirement to demonstrate a link
between diagnostic performance and health outcomes
may have already been met by the existing evidence-base
for either component of the hybrid technology deployed
alone. In the case of FDG-PET/MRI for patients with sus-
pected recurrent or residual malignancy, such links have
already been demonstrated for the PET component for a
range of tumour types. Secondly, rather than rely solely on
technology assessments of the new device, the evidence-
base for hybrid technologies such as PET/MRI can be sup-
plemented by studies comparing the components of the
hybrid technology deployed separately. In the current
study, this approach to evidence-synthesis has identified
additional support for the application of PET/MRI in
the assessment of suspected recurrent of residual ma-
lignancy by providing supplementary evidence of im-
proved detection of malignant lesions in bone and liver
whilst preserving the effectiveness of PET for lymph
node recurrence. Furthermore, a review of studies
assessing therapeutic impact of FDG-PET/MRI suggests
a greater likelihood for change in clinical management
when FDG-PET/MRI is used for assessment of sus-
pected residual or recurrent disease rather than tumour
staging. Thus, supplementing the evidence-base for
FDG-PET/MRI with studies that compare the compo-
nents of this hybrid technology deployed separately
suggests that FDG-PET/MRI is likely to be clinical ef-
fective for the investigation of patients with a range of
suspected residual or recurrent cancers. This indication
should therefore be prioritised for further health tech-
nology assessment.
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